Drugs / LQT-1213
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05759962 | Sep 2022 → Mar 2023 | long QT syndrome | Thryv Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05906732 | Mar 2023 → May 2024 | long QT syndrome | Thryv Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LQT-1213 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05906732 ↗ |
| Action | Inhibit | “serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor” NCT05759962 ↗ |
| Route | Oral | “single oral dose” NCT05759962 ↗ |
| Target | SGK1 | “serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor” NCT05759962 ↗ |